Key result
Daratumumab shows early feasibility for targeting plasma cells in heart transplant antibody-mediated rejection.
Why the study?
Does daratumumab improve outcomes in heart transplant patients with antibody-mediated rejection?
Does daratumumab improve outcomes in heart transplant patients with antibody-mediated rejection?
This study reports a single-center experience using daratumumab for antibody-mediated rejection after heart transplantation.
Daratumumab for AMR after heart transplant should not yet change practice; leaves open efficacy questions for prospective trials.
No takes yet. Share an insight, caveat, or question.
Irache et al. (2026) studied this question. Daratumumab was evaluated for targeting plasma cells in antibody-mediated rejection after heart transplantation in a single-center experience.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: